English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/134484
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

AuthorsCarrancio, Soraya; Romo, Carlos; López-Holgado, Natalia; Muntión, Sandra; Briñón, Jesús G.; San Miguel, Jesús F. ; Cañizo, María Consuelo del; Sánchez-Guijo, Fermín M.
KeywordsCordon blood transplantation
Bone marrow microenvironment
Hematopoietic engraftmen
Mesenchymal stem cells (MSCs)
Issue Date2013
PublisherCognizant Communication Corporation
CitationCell Transplantation 22(7): 1171-1183 (2013)
AbstractHematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.
DescriptionLicencia Creative Commons Reconocimiento-No comercial.-- et al.
Publisher version (URL)http://dx.doi.org/10.3727/096368912X657431
URIhttp://hdl.handle.net/10261/134484
DOI10.3727/096368912X657431
Identifiersdoi: 10.3727/096368912X657431
issn: 0963-6897
e-issn: 1555-3892
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
stemcellengraftment.pdf502,89 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.